GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » EPS (Diluted)

Ind-Swift Laboratories (NSE:INDSWFTLAB) EPS (Diluted) : ₹7.36 (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories EPS (Diluted)?

Ind-Swift Laboratories's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₹3.29. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.36.

Ind-Swift Laboratories's EPS (Basic) for the three months ended in Dec. 2023 was ₹3.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.36.

Ind-Swift Laboratories's EPS without NRI for the three months ended in Dec. 2023 was ₹3.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₹10.72.

During the past 12 months, Ind-Swift Laboratories's average EPS without NRIGrowth Rate was 204.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Ind-Swift Laboratories's highest 3-Year average EPS without NRI Growth Rate was 38.20% per year. The lowest was 14.30% per year. And the median was 23.40% per year.


Ind-Swift Laboratories EPS (Diluted) Historical Data

The historical data trend for Ind-Swift Laboratories's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories EPS (Diluted) Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.96 -4.28 -4.28 -4.28 8.10

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.65 -4.21 2.92 5.36 3.29

Competitive Comparison of Ind-Swift Laboratories's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's PE Ratio falls into.



Ind-Swift Laboratories EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ind-Swift Laboratories's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(475.966-0)/58.761
=8.10

Ind-Swift Laboratories's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(194.188-0)/59.024
=3.29

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ind-Swift Laboratories EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines